title: Hemagglutinating virus of Japan envelope (HVJ-E) can enhance the immune responses of swine immunized with killed PRRSV vaccine.
abstract: Porcine reproductive and respiratory syndrome virus (PRRSV) is an economically detrimental pig pathogen that causes significant losses for the pig industry. The immunostimulatory effects of hemagglutinating virus of Japan envelope (HVJ-E) in cancer therapy and the adjuvant efficacy of HVJ-E have been previously evaluated. The objective of this study was to investigate the adjuvant effects of HVJ-E on immunization with killed PRRSV vaccine, and to evaluate the protective effects of this immunization strategy against virulent PRRSV infection in piglets. Next, the PRRSV-specific antibody response, lymphocyte proliferation, PRRSV-specific IL-2, IL-10 and IFN-γ production, and the overall protection efficacy were evaluated to assess the immune responses of the piglets. The results showed that the piglets inoculated simultaneously with killed PRRSV vaccine and HVJ-E had a significantly stronger immune response than those inoculated with killed PRRSV vaccine alone. Our results suggest that HVJ-E could be employed as an effective adjuvant to enhance the humoral and cellular responses of piglets to PRRSV.
authors: State Key Laboratory of Agrobiotechnology, College of Veterinary Medicine, China Agricultural University, Beijing 100094, China.
authors: Zhihong
authors: Z
authors: Dai
authors: Quan
authors: Q
authors: Zhang
authors: Zaishi
authors: Z
authors: Wang
authors: Zhongqiu
authors: Z
authors: Zhang
authors: Pengju
authors: P
authors: Guo
authors: Deming
authors: D
authors: Zhao
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D016207:Cytokines / Q000276:immunology; D019318:Porcine Reproductive and Respiratory Syndrome / Q000276:immunology / Q000517:prevention & control*; D019316:Porcine respiratory and reproductive syndrome virus; D029082:Sendai virus / Q000276:immunology*; D013552:Swine; D014759:Viral Envelope Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D014759:Viral Envelope Proteins; D014765:Viral Vaccines